Nothing Special   »   [go: up one dir, main page]

PE20080425A1 - Formulacion aerosol para la inhalacion de beta-agonistas - Google Patents

Formulacion aerosol para la inhalacion de beta-agonistas

Info

Publication number
PE20080425A1
PE20080425A1 PE2007001122A PE2007001122A PE20080425A1 PE 20080425 A1 PE20080425 A1 PE 20080425A1 PE 2007001122 A PE2007001122 A PE 2007001122A PE 2007001122 A PE2007001122 A PE 2007001122A PE 20080425 A1 PE20080425 A1 PE 20080425A1
Authority
PE
Peru
Prior art keywords
beta
alkyl
agonists
inhalation
aerosol formulation
Prior art date
Application number
PE2007001122A
Other languages
English (en)
Inventor
Michael Nowak
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080425A1 publication Critical patent/PE20080425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN BETA-AGONISTA DE FORMULA (1) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, ALQUILO(C1-C4) O JUNTOS FORMAN ALQUILENO(C1-C6); R3 ES H, HALOGENO, OH, ALQUILO(C1-C4) U O-ALQUILO; X- ES UN ANION TAL COMO CLORURO, BROMURO, SULFATO, ACETATO, ENTRE OTROS; B) CLORURO DE BENZALCONIO EN UNA CANTIDAD DE 1 A 50MG POR 100ML DE SOLUCION; C) UN FORMADOR DE COMPLEJOS EN UNA CANTIDAD DE 1 A 50MG POR 100ML DE SOLUCION; D) UN DISOLVENTE TAL COMO AGUA, ETANOL O UNA MEZCLA DE LOS MISMOS EN DONDE EL ETANOL SE ENCUENTRA DE 5% A 99%; E) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO, PROPILGALATO, ENTRE OTROS. DICHA COMPOSICION TIENE UN pH DE 2,5 A 6,5 SIENDO UTIL PARA EL TRATAMIENTO DE ENFISEMA PULMONAR, ASMA, FIBROSIS QUISTICA, BRONQUITIS
PE2007001122A 2006-08-22 2007-08-20 Formulacion aerosol para la inhalacion de beta-agonistas PE20080425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119274 2006-08-22

Publications (1)

Publication Number Publication Date
PE20080425A1 true PE20080425A1 (es) 2008-06-16

Family

ID=38564599

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001122A PE20080425A1 (es) 2006-08-22 2007-08-20 Formulacion aerosol para la inhalacion de beta-agonistas

Country Status (9)

Country Link
US (1) US20080053430A1 (es)
EP (1) EP2056837A1 (es)
JP (1) JP2010501523A (es)
AR (1) AR062477A1 (es)
CA (1) CA2661442A1 (es)
PE (1) PE20080425A1 (es)
TW (1) TW200820974A (es)
UY (1) UY30555A1 (es)
WO (1) WO2008023005A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
BRPI1009578A2 (pt) * 2009-03-24 2016-03-08 Chevron Usa Inc método e sistema para otimizar características de fratura em um modelo de poço

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos

Also Published As

Publication number Publication date
WO2008023005A1 (de) 2008-02-28
EP2056837A1 (de) 2009-05-13
JP2010501523A (ja) 2010-01-21
CA2661442A1 (en) 2008-02-28
US20080053430A1 (en) 2008-03-06
UY30555A1 (es) 2008-03-31
AR062477A1 (es) 2008-11-12
TW200820974A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
PE20080425A1 (es) Formulacion aerosol para la inhalacion de beta-agonistas
HRP20171614T1 (hr) Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
ES2579936T3 (es) Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
MEP51008A (en) Aerosol formulation for inhalation, containing an anticholinergic agent
ES2314408T3 (es) Formulaciones de hfc en solucion que contienen un anticolinergico.
PE20061162A1 (es) Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR050902A1 (es) Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
NO20062877L (no) Stabile liposomsammensetninger som omfatter lipofile aminholdige farmasoytiske midler
ECSP088335A (es) Compuestos de pirimidina amida como inhibidores de pgds
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
UY26570A1 (es) Carboxamidas de pirimidina útiles como inhibidores de isozimas pde4
NZ721662A (en) Amine and amine oxide surfactants for controlling herbicide spray drift
BRPI0514058A (pt) composições para limpeza de substratos microeletrÈnicos
PE20061437A1 (es) Composicion en emulsion que comprende derivados de cicloalqueno, estable en rango acido
CL2008001982A1 (es) Acido (2s)-2-{[3´-cloro-4´-[2,2-dimetilpirrolidin-1-il) carbonil]-5-fluorobifenil-2-il]oxi}propanoico y su sal 2-metilpropan-2-amina; formas cristalinas de la sal y del acido libre; compuestos intermediarios; y uso en el tratamiento de asma, rinitis y enfermedad pulmonar obstructiva cronica.
CL2007001282A1 (es) Compuestos derivados de 2-piridona; proceso de preparacion; composicion farmaceutica; proceso de preparacion; y uso para el tratamiento de enfermedades tales como enfisema pulmonar, bronquitis, asma, soriasis, aterosclerosis, artritis reumatoide, entre otras.
AR038644A1 (es) Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada
MX2010010832A (es) Formulacion acuosa estable que contiene esporas.
ES2572808T3 (es) Derivados de piridincarboxamida y su utilización como plaguicidas
JP2016534088A5 (es)
PE20060311A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
JP2016527220A5 (es)
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
AR063854A1 (es) Beta-1,6-disacaridos de glucosamina funcionalizados y un procedimiento para su preparacion. composiciones farmaceuticas

Legal Events

Date Code Title Description
FD Application declared void or lapsed